IRF1 and metastatic melanoma: In their original paper, Ulloa-Montoya et al. (2013) identified 84 gene expression signatures associated with response to MAGE-A3 immunotherapy in metastatic melanoma and non-small-cell lung cancer, whereas 61 of the 84 genes were chosen as biomarker genes by our proposed method (e.g., CD86, CCL5, and IRF1).